SCHEMBL6715506

SCHEMBL6715506

CCOc1ccc(-c2ccc3cc4n(c3c2)CCNCC4)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 8/20 0.45
HTR2C P28335 8/20 0.45
NMT1 P30419 1/20 0.39
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
MCHR1 Q99705 2/20 0.33
SRC P12931 2/20 0.33
RAD52 P43351 1/20 0.33
KMT2A Q03164 1/20 0.33
HTR1A P08908 1/20 0.33
HTR7 P34969 1/20 0.33
CCNT1 O60563 1/20 0.33
CDK9 P50750 1/20 0.33
SYK P43405 1/20 0.32
AURKB Q96GD4 1/20 0.32
INCENP Q9NQS7 1/20 0.32
ACACB O00763 1/20 0.32
ACACA Q13085 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6713959 0.92 HTR2A (0.45) HTR2AHTR2CNMT1MMP2MMP3
SCHEMBL6714393 0.89 HTR2A (0.47) HTR2AHTR2CSRCKMT2A
SCHEMBL6715798 0.88 HTR2A (0.58) HTR2AHTR2CMCHR1HTR1AHTR7
SCHEMBL6718901 0.84 HTR2C (0.42) HTR2AHTR2CSRCRAD52KMT2A
SCHEMBL6715426 0.83 HTR2A (0.52) HTR2AHTR2CHTR1AHTR7
SCHEMBL6712443 0.81 HTR2A (0.50) HTR2AHTR2CNMT1HTR1AHTR7
SCHEMBL6714104 0.81 HTR2A (0.54) HTR2AHTR2CHTR1AHTR7
SCHEMBL6718479 0.81 HTR2A (0.55) HTR2AHTR2CHTR1AHTR7
SCHEMBL6714119 0.80 HTR2A (0.47) HTR2AHTR2CSRC
SCHEMBL6710991 0.80 HTR2A (0.60) HTR2AHTR2CHTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US claimed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US claimed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US claimed
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US disclosed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US disclosed
EP-1328525-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-A]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-23 EP disclosed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US disclosed
WO-2001072752-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HTR1D, HTR1A, HTR1E HTR2A 18/4885HTR2C 7/4885NMT1 3305/4885
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HCRTR2, NR2C2, RCOR3 HTR2A 1403/4885HTR2C 553/4885NMT1 3577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.